Nephrogenic Systemic Fibrosis
We Represent Victims Nationwide
Nephrogenic Systemic Fibrosis made its appearance in 1997, when the first case was diagnosed, and it was formally recognized in 2000.
At first it was seen as a skin disorder and was called Nephrogenic Fibrosing Dermopathy (NFD). But gradually wider symptoms were described and it is now considered a systemic disorder, as it affects internal organs as well as the skin.
NFS has been connected to the use of Gadolinium, a contrast agent used in preparation for MRIs (Magnetic Resonance Imaging) and MRAs (Magnetic Resonance Angiogram). Gadolinium is an ingredient in the injection, which is given before these procedures, with the purpose of creating visual contrast on the printed films, between normal and abnormal tissue. This enables the doctor to see your condition more clearly.
Since this is a recently discovered disease, there is little known about it and few studies have been done. The FDA approved Gadolinium in 1988, but since the number of NSF cases has been increasing, the FDA issued Advisories to medical professionals, warning them to use all possible caution when treating patients with chronic kidney disease.
If you have kidney disease and have had any MRIs or MRAs since 1988, and you notice any symptoms that suggest NSF, contact your doctor immediately. Our Nephrogenic Systemic Fibrosis attorneys are experienced both in pharmaceutical injury litigation as well as medical malpractice litigation. We represent NSF victims throughout the US and we work on a contingent basis. This means, we won’t charge you any attorneys’ fees up front. We get paid only after we bring about a recovery of damages for our clients.

CONTACT JOE FLORES, A NURSE PRACTITIONER AND A TRIAL ATTORNEY WHO CAN COMPETENTLY EVALUATE YOUR CLAIM TODAY.
361.887.8670 OR JOE@FLORESLAWFIRM.COM